Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Sep;18(9):2285-2294.
doi: 10.1111/ajt.14893. Epub 2018 May 15.

Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study

Ramsey R Hachem  1 , Malek Kamoun  2 , Marie M Budev  3 , Medhat Askar  4 , Vivek N Ahya  5 , James C Lee  5 , Deborah J Levine  6 , Marilyn S Pollack  7 , Gundeep S Dhillon  8 , David Weill  8 , Kenneth B Schechtman  9 , Lorriana E Leard  10 , Jeffrey A Golden  10 , LeeAnn Baxter-Lowe  11 , Thalachallour Mohanakumar  12 , Dolly B Tyan  13 , Roger D Yusen  1
Affiliations
Observational Study

Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study

Ramsey R Hachem et al. Am J Transplant. 2018 Sep.

Abstract

Donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) are associated with worse outcomes after lung transplantation. To determine the incidence and characteristics of DSA early after lung transplantation, we conducted a prospective multicenter observational study that used standardized treatment and testing protocols. Among 119 transplant recipients, 43 (36%) developed DSA: 6 (14%) developed DSA only to class I HLA, 23 (53%) developed DSA only to class II HLA, and 14 (33%) developed DSA to both class I and class II HLA. The median DSA mean fluorescence intensity (MFI) was 3197. We identified a significant association between the Lung Allocation Score and the development of DSA (HR = 1.02, 95% CI: 1.001-1.03, P = .047) and a significant association between DSA with an MFI ≥ 3000 and acute cellular rejection (ACR) grade ≥ A2 (HR = 2.11, 95% CI: 1.04-4.27, P = .039). However, we did not detect an association between DSA and survival. We conclude that DSA occur frequently early after lung transplantation, and most target class II HLA. DSA with an MFI ≥ 3000 have a significant association with ACR. Extended follow-up is necessary to determine the impact of DSA on other important outcomes.

Keywords: clinical research/practice; histocompatibility; lung transplantation/pulmonology; major histocompatibility complex (MHC); monitoring: immune; rejection: T cell mediated (TCMR); rejection: antibody-mediated (ABMR).

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

The authors have no conflicts of interest to disclose as described by the American Journal of Transplantation.

Figures

Figure 1
Figure 1
Flow diagram: study screening and eligibility. IVIG: intravenous immune globulin. CMV-IG: cytomegalovirus immune globulin.
Figure 2
Figure 2
Kaplan-Meier freedom from post-transplant donor-specific HLA antibodies (DSA) during the study period. Thin dashed lines depict upper and lower bounds of 95% confidence interval.
Figure 3
Figure 3
A. The proportion of patients who developed post-transplant donor-specific HLA antibodies (DSA) stratified by the number of DSA specificities. B. The proportion of patients who developed post-transplant DSA stratified by DSA specificity. C. Post-transplant DSA mean fluorescence intensity (MFI) stratified by HLA locus. Boxes extend from the 25th to the 75th percentiles, whiskers extend to the largest and smallest values within 1.5 times box lengths, and the line within the boxes represents the median. Solid circles represent outlier cases between 1.5 and 3 box lengths from the upper edge of the boxes.
See this image and copyright information in PMC

References

    1. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant. 2002;21:226–232. - PubMed
    1. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: Life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant. 2001;20:518–524. - PubMed
    1. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351:24–27. - PubMed
    1. Singer JP, Singer LG. Quality of life in lung transplantation. Semin Respir Crit Care Med. 2013;34:421–430. - PMC - PubMed
    1. Singer LG, Chowdhury NA, Faughnan ME, et al. Effects of recipient age and diagnosis on health-related quality of life benefit of lung transplantation. Am J Respir Crit Care Med. 2015;192:965–973. - PubMed

Publication types

MeSH terms